Trial Profile
Multiple-Dose, Open-Label, Randomized, Safety and Pharmacokinetic Study of Tipranavir in Combination With Low-Dose Ritonavir in HIV-Infected Pediatric Patients.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Tipranavir (Primary) ; Ritonavir
- Indications HIV infections; HIV-1 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 17 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Apr 2010 Planned end date changed from 1 Mar 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.
- 30 Jun 2009 Trial phase changed from I/II to I as reported by ClinicalTrials.gov.